Ulrike Weyer-Czernilofsky
Overview
Explore the profile of Ulrike Weyer-Czernilofsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
437
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gollner A, Rudolph D, Weyer-Czernilofsky U, Baumgartinger R, Jung P, Weinstabl H, et al.
Mol Cancer Ther
. 2024 Sep;
23(12):1689-1702.
PMID: 39259562
p53 is known as the guardian of the genome and is one of the most important tumor suppressors. It is inactivated in most tumors, either via tumor protein p53 (TP53)...
2.
Hao X, Bahia R, Cseh O, Bozek D, Blake S, Rinnenthal J, et al.
Neuro Oncol
. 2022 Dec;
25(5):913-926.
PMID: 36521007
Background: The tumor suppressor TP53 (p53) is frequently mutated, and its downstream effectors inactivated in many cancers, including glioblastoma (GBM). In tumors with wild-type status, p53 function is frequently attenuated...
3.
Wu X, Seraia E, Hatch S, Wan X, Ebner D, Aroldi F, et al.
Oncogene
. 2021 Nov;
41(4):476-488.
PMID: 34773074
We recently reported that genetic or pharmacological inhibition of insulin-like growth factor receptor (IGF-1R) slows DNA replication and induces replication stress by downregulating the regulatory subunit RRM2 of ribonucleotide reductase,...
4.
Rieunier G, Wu X, Harris L, Mills J, Nandakumar A, Colling L, et al.
Cancer Res
. 2021 Jan;
81(8):2128-2141.
PMID: 33509941
Inhibition of IGF receptor (IGF1R) delays repair of radiation-induced DNA double-strand breaks (DSB), prompting us to investigate whether IGF1R influences endogenous DNA damage. Here we demonstrate that IGF1R inhibition generates...
5.
Weyer-Czernilofsky U, Hofmann M, Friedbichler K, Baumgartinger R, Adam P, Solca F, et al.
Mol Cancer Ther
. 2020 Feb;
19(4):1059-1069.
PMID: 32054790
Androgen deprivation therapy and second-generation androgen receptor signaling inhibitors such as enzalutamide are standard treatments for advanced/metastatic prostate cancer. Unfortunately, most men develop resistance and relapse; signaling via insulin-like growth...
6.
Rieunier G, Wu X, Macaulay V, Lee A, Weyer-Czernilofsky U, Bogenrieder T
Clin Cancer Res
. 2019 Feb;
25(12):3479-3485.
PMID: 30745299
Bone metastases are a frequent complication of cancer that are associated with considerable morbidity. Current treatments may temporarily palliate the symptoms of bone metastases but often fail to delay their...
7.
Aleksic T, Gray N, Wu X, Rieunier G, Osher E, Mills J, et al.
Cancer Res
. 2018 May;
78(13):3497-3509.
PMID: 29735545
Internalization of ligand-activated type I IGF receptor (IGF1R) is followed by recycling to the plasma membrane, degradation or nuclear translocation. Nuclear IGF1R reportedly associates with clinical response to IGF1R inhibitory...
8.
Hirt U, Waizenegger I, Schweifer N, Haslinger C, Gerlach D, Braunger J, et al.
Oncogenesis
. 2018 Feb;
7(2):21.
PMID: 29472531
Focal adhesion kinase (FAK), a non-receptor tyrosine kinase, has attracted interest as a target for pharmacological intervention in malignant diseases. Here, we describe BI 853520, a novel ATP-competitive inhibitor distinguished...
9.
Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer
Ireland L, Santos A, Campbell F, Figueiredo C, Hammond D, Ellies L, et al.
Oncogene
. 2018 Jan;
37(15):2022-2036.
PMID: 29367764
Breast cancer remains the leading cause of cancer death in women owing to metastasis and the development of resistance to established therapies. Macrophages are the most abundant immune cells in...
10.
Simpson A, Petnga W, Macaulay V, Weyer-Czernilofsky U, Bogenrieder T
Target Oncol
. 2017 Aug;
12(5):571-597.
PMID: 28815409
Despite a strong preclinical rationale for targeting the insulin-like growth factor (IGF) axis in cancer, clinical studies of IGF-1 receptor (IGF-1R)-targeted monotherapies have been largely disappointing, and any potential success...